Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Abderrahim Oukessou"'
Autor:
Thomas John, Hiroshi Sakai, Satoshi Ikeda, Ying Cheng, Kazuo Kasahara, Yuki Sato, Yoshiro Nakahara, Masayuki Takeda, Hiroyasu Kaneda, Helong Zhang, Makoto Maemondo, Koichi Minato, Takeshi Hisada, Yuki Misumi, Miyako Satouchi, Katsuyuki Hotta, Ang Li, Abderrahim Oukessou, Shun Lu
Publikováno v:
International journal of clinical oncology. 27(4)
Background CheckMate 9LA, a phase 3, randomized, open-label study in first-line advanced non-small cell lung cancer (NSCLC), showed significantly improved overall survival (OS) with nivolumab plus ipilimumab combined with 2 cycles of chemotherapy ver
Autor:
Nobukazu Fujimoto, Laurent Greillier, Thierry Jahan, Aaron S. Mansfield, Praveen Aanur, Yolanda Bautista, Solange Peters, Christine Baudelet, Abderrahim Oukessou, Anna K. Nowak, Dariusz M. Kowalski, Arnaud Scherpereel, Anne S. Tsao, Scott J. Antonia, Jerónimo Rodríguez-Cid, Paul Baas, Youssef Oulkhouir, Gérard Zalcman, Sanjay Popat, Robin Cornelissen, Francesco Grossi
Publikováno v:
The Lancet Digital Health
The Lancet Digital Health, 2021, 397 (10272), pp.375-386. ⟨10.1016/S0140-6736(20)32714-8⟩
The Lancet, 397(10272), 375-386. ELSEVIER SCIENCE INC
The Lancet
The Lancet, 2021, 397 (10272), pp.375-386. ⟨10.1016/S0140-6736(20)32714-8⟩
The Lancet, 397(10272), 375-386. Elsevier Ltd.
The Lancet Digital Health, 2021, 397 (10272), pp.375-386. ⟨10.1016/S0140-6736(20)32714-8⟩
The Lancet, 397(10272), 375-386. ELSEVIER SCIENCE INC
The Lancet
The Lancet, 2021, 397 (10272), pp.375-386. ⟨10.1016/S0140-6736(20)32714-8⟩
The Lancet, 397(10272), 375-386. Elsevier Ltd.
Background: Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::645b83946b062223362a708abde6703c
https://inria.hal.science/hal-03526460
https://inria.hal.science/hal-03526460
Autor:
Pierre-Jean Souquet, David P. Carbone, Michael Schenker, Shun Lu, S. Meadows-Shropshire, A. Alexandru, Pamela Salman, Hiroshi Sakai, Jaafar Bennouna, Maurice Pérol, Enriqueta Felip, Alejo Lingua, J. Yan, Juliana Janoski de Menezes, B. Zurawski, Martin Reck, Arnaud Scherpereel, C. Martin, Eduardo Richardet, Abderrahim Oukessou, Tudor-Eliade Ciuleanu, Manuel Cobo, O. Juan-Vidal, Pedro Rafael Martins De Marchi, Thomas John, Luis Paz-Ares, Shruti Agrawal
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Lancet
Lancet, Elsevier, 2021, 22 (2), pp.198-211. ⟨10.1016/S1470-2045(20)30641-0⟩
The Lancet
The Lancet, 2021, 22 (2), pp.198-211. ⟨10.1016/S1470-2045(20)30641-0⟩
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Lancet
Lancet, Elsevier, 2021, 22 (2), pp.198-211. ⟨10.1016/S1470-2045(20)30641-0⟩
The Lancet
The Lancet, 2021, 22 (2), pp.198-211. ⟨10.1016/S1470-2045(20)30641-0⟩
Erratum in Correction to Lancet Oncol 2021; 22: 198-211. [No authors listed] Lancet Oncol. 2021 Mar;22(3):e92. doi: 10.1016/S1470-2045(21)00082-6. PMID: 33662299 No abstract available.; International audience; Background: First-line nivolumab plus ip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa94d86fd54759cc80a6aa8c6a4c99f6
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13780
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13780
Autor:
Ben C. Creelan, Ang Li, Mohamed K. Mohamed, Nivedita Aanur, Shruti Agrawal, Jason C. Chandler, Kenneth B. Blankstein, Michael McCleod, Craig H. Reynolds, Abderrahim Oukessou, Leora Horn, Petros Nikolinakos, David R. Spigel, Tarek Mekhail, David M. Waterhouse
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:679-686
Nivolumab has been administered using a 60-min infusion time. Reducing this time to 30 min would benefit both patients and infusion facilities. This analysis compared the safety of 30- and 60-min infusions of nivolumab in patients with previously tre
Publikováno v:
The Lancet. 398:302
Autor:
J McKendrick, Catherine Davis, David Cella, Teresa Zyczynski, Ravi Vij, Antonio Palumbo, Abderrahim Oukessou, Amber Kudlac
Publikováno v:
Annals of Hematology
Treatment of relapsed/refractory multiple myeloma (RRMM) aims to prolong survival while maintaining health-related quality of life (HRQoL) by managing disease-related symptoms and complications—one of the most frequent and debilitating being bone p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f4777a1be5ff8b83930418b88d73890
https://hdl.handle.net/10453/130893
https://hdl.handle.net/10453/130893
Autor:
B. Bregman, Agnès Guerci-Bresler, Mauricette Michallet, Martine Gardembas, Anne Vekhoff, Michel Tulliez, Françoise Huguet, Kamel Ghomari, Nathalie Cambier, Selim Corm, Abderrahim Oukessou
Publikováno v:
Current Medical Research and Opinion. 26:307-317
To assess real-life treatment practices with imatinib for chronic-phase chronic myeloid leukaemia (CP-CML) in France.In the observational 'Unmet Needs in CML' (UNIC) study of CML management in Europe, case report forms were completed retrospectively
Autor:
Hartmut Goldschmidt, Catherine Davis, Sergey Popov, Gordon Cook, David Cella, Antonio Palumbo, David J. Kuter, Ravi Vij, Brian G.M. Durie, Abderrahim Oukessou, Philippe Moreau, Teresa Zyczynski
Publikováno v:
Blood. 126:2093-2093
Introduction: Multiple myeloma (MM) is a B-cell hematologic malignancy associated with significant disease and treatment-related morbidities. Therapies including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) have improved treatment o
Autor:
Jean-Luc Laï, B. Bregman, Claude Preudhomme, Ariane Leroyer, Stéphanie Poulain, Abderrahim Oukessou, Thierry Facon, Jean-Baptiste Micol, Agnès Daudignon, Selim Corm
Publikováno v:
Journal of Clinical Oncology. 26:7088-7088
7088 Background: We conducted a retrospective study in the Nord Pas de Calais (NPC) area of France (4 millions inhabitants) in order to assess the CML prevalence since the introduction of imatinib in 2000. Methods: We recorded from 1985 to 2006 all n
Autor:
Mauricette Michallet, Michel Tulliez, Sélim Corm, Martine Gardembas, Françoise Huguet, Abderrahim Oukessou, Bruno Bregman, Anne Vekhoff, Kamel Ghomari, Nathalie Cambier, Agnès Guerci-Bresler
Publikováno v:
Current Medical Research & Opinion; Jan2010, Vol. 26 Issue 2, p307-317, 11p